Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results